Cancer R&D 2024 has wrapped up successfully. We’re grateful for your interest and interaction with Alfa Cytology. We’re eager to continue providing our expertise in cancer drug development. Let’s look back on these memorable moments!
Learn More
Breast cancer remains a leading cause of cancer-related morbidity and mortality globally, necessitating advanced research methodologies to unravel its complexities. At Alfa Cytology, we provide our clients integrative omics analysis for breast cancer.
Integrative omics analysis combines multiple levels of biological data from genomics, transcriptomics, proteomics, and metabolomics to provide a comprehensive approach to understanding the underlying mechanisms of breast cancer. This multilevel strategy not only helps to identify novel biomarkers, but also facilitates the development of personalized treatment strategies. Recent studies have demonstrated that breast cancer is not a single disease but rather a collection of genetically distinct subtypes, each exhibiting unique molecular characteristics.
Fig.1 Transcriptomic, metabolomic and proteomic profiles were obtained from BC tissue samples. (Freitas A. J. A. d., et al., 2021)
For instance, the heterogeneity within the Luminal A, Luminal B, HER2-enriched, and triple-negative breast cancer (TNBC) subtypes highlights the necessity for tailored treatment approaches. Integrative omics can elucidate the pathways and interactions involved in tumor biology, providing insights into potential therapeutic targets.
At Alfa Cytology, we specialize in a range of analyses tailored to breast cancer research. Our comprehensive suite of services enables our clients to explore the multi-dimensional landscape of tumor biology.
For more information on how Alfa Cytology can support your research in breast cancer through integrative omics analysis, please contact us. Our team of experts is dedicated to providing high-quality, customized solutions that meet your specific research needs.
Reference